3,6-Diamino-5-cyan-1-methyl-1H-pyrazolo<3,4-b>pyridin | 1901-69-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 3,6-Diamino-5-cyan-1-methyl-1H-pyrazolo<3,4-b>pyridin
• 英文别名: 3,6-diamino-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile；3,6-Diamino-1-methylpyrazolo[3,4-b]pyridine-5-carbonitrile
• CAS: 1901-69-5
• 化学式: C₈H₈N₆
• 分子量: 188.192
• InChiKey: UADYXCCWXCCSER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 3,6-Diamino-5-cyan-1-methyl-1H-pyrazolo<3,4-b>pyridin 反应 3.0h， 以82%的产率得到N-(6-amino-5-cyano-1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)acetamide
  参考文献：
  名称：

  蛋白激酶抑制剂3,6-二氨基-1 H-吡唑并[3,4- b ]吡啶衍生物的合成及生物学评价

  摘要：

  报道了许多不同取代的3,6-二氨基-1 H-吡唑并[3,4- b ]吡啶衍生物的合成和生物学评价。从抑制结果中选择与疾病相关的蛋白激酶[IC 50（μM）DYRK1A = 11；CDK5 = 0.41；GSK-3 = 1.5]我们已经观察到3,6-二氨基-4-苯基-1 H-吡唑并[3,4- b ]吡啶-5-甲腈（4）构成了潜在的新颖且简单的先导化合物用于治疗阿尔茨海默氏病的药物。

  DOI：

  10.1016/j.bmcl.2009.06.099
• 作为产物：
  描述：

  2-氨基-6-氯-3,5-二氰基吡啶 、 甲基肼 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.25h， 以99%的产率得到3,6-Diamino-5-cyan-1-methyl-1H-pyrazolo<3,4-b>pyridin
  参考文献：
  名称：

  蛋白激酶抑制剂3,6-二氨基-1 H-吡唑并[3,4- b ]吡啶衍生物的合成及生物学评价

  摘要：

  报道了许多不同取代的3,6-二氨基-1 H-吡唑并[3,4- b ]吡啶衍生物的合成和生物学评价。从抑制结果中选择与疾病相关的蛋白激酶[IC 50（μM）DYRK1A = 11；CDK5 = 0.41；GSK-3 = 1.5]我们已经观察到3,6-二氨基-4-苯基-1 H-吡唑并[3,4- b ]吡啶-5-甲腈（4）构成了潜在的新颖且简单的先导化合物用于治疗阿尔茨海默氏病的药物。

  DOI：

  10.1016/j.bmcl.2009.06.099

文献信息

• Studies on the acetylation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile derivatives
  作者：Mourad Chioua、Elena Soriano、Abdelouahid Samadi、J. Marco-Contelles

  DOI：10.1002/jhet.403

  日期：——

  Abstract magnified image The acetylation reaction of the differently substituted 3,6‐diamino‐1H‐pyrazolo[3,4‐b]pyridine‐5‐carbonitrile derivatives 1, 2, 3, 4, 5, 6 is reported. The structure of the resulting acetamides has been investigated and confirmed by analytical, spectroscopic, and chemical transformations. From these studies, we conclude that, in general, under mild conditions, and using acetic anhydride, when free, the N(1)H moiety is a more reactive center respect to the C(3)NH2 and C(6)NH2 groups. This trend is reversed when no steric hindrance due to presence of a phenyl group at C4 drives the preferred acetylation to C(3)NH2, as it is evident by comparing the observed results from precursor 1 with 3. When N1 is blocked, the (C3)NH2 group undergoes preferential acetylation over the (C6)NH2 site, which only has been mono (or diacetylated) at reflux. Computational analyses based on DFT studies have been extensively used to explain the observed reactivities. J. Heterocyclic Chem., (2010).
• Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors
  作者：Mourad Chioua、Abdelouahid Samadi、Elena Soriano、Olivier Lozach、Laurent Meijer、José Marco-Contelles

  DOI：10.1016/j.bmcl.2009.06.099

  日期：2009.8

  biological evaluation of a number of differently substituted 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives are reported. From the inhibition results on a selection of disease-relevant protein kinases [IC50 (μM) DYRK1A = 11; CDK5 = 0.41; GSK-3 = 1.5] we have observed that 3,6-diamino-4-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile (4) constitutes a potential new and simple lead compound in the

  报道了许多不同取代的3,6-二氨基-1 H-吡唑并[3,4- b ]吡啶衍生物的合成和生物学评价。从抑制结果中选择与疾病相关的蛋白激酶[IC 50（μM）DYRK1A = 11；CDK5 = 0.41；GSK-3 = 1.5]我们已经观察到3,6-二氨基-4-苯基-1 H-吡唑并[3,4- b ]吡啶-5-甲腈（4）构成了潜在的新颖且简单的先导化合物用于治疗阿尔茨海默氏病的药物。